LIGAND PHARMACEUTICALS INC
LGNDNasdaq
$303.39
↑ +2.3%Jul 17 close · end-of-day
Price
1Y↑ +134.0%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$6.0B
Enterprise Value
$5.3B
P/E
39.6
P/S
22.0
P/B
6.0
EV/EBITDA
41.1
PEG
—
FCF Yield
2.0%
Dividend Yield
—
Revenue (TTM)
$274.5M
Net Income (TTM)
$153.6M
Free Cash Flow (TTM)
$123.0M
Gross Margin
—
Operating Margin
34.5%
Net Margin
56.0%
ROE
15.4%
ROIC
36.0%
Debt / Equity
—
Net Cash
$779.4M
Return 1Y
+120.5%
Company profile
Ligand Pharmaceuticals Incorporated focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by Streptococcus pneumoniae. The company also offers Rylaze, a recombinant erwinia asparaginase, and Nexterone, a captisol-enabled formulation of amiod
- CEO
- John L. Higgins
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 80
- Headquarters
- California
- Website
- ligand.com
Management & directors
- Reardon AndrewCLO & Secretary
- Davis Todd CChief Executive Officer
- Espinoza OctavioChief Financial Officer
Roles derived from SEC Form 4 filings.
Earnings
LGND Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$51.7M↑ +14.1%
Diluted EPS-$0.67↓ -69.7%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $163.6M | $241.5M | $196.2M | $131.3M | $167.1M | $268.1M |
| Gross profit | — | — | — | — | — | — |
| Operating income | $37.5M | $103.9M | $3.0M | $11.9M | -$22.6M | $41.0M |
| Net income | -$3.0M | $57.1M | -$33.4M | $52.2M | -$4.0M | $124.5M |
| Diluted EPS | -$0.18 | $3.31 | -$1.98 | $2.94 | -$0.22 | $6.13 |
| Operating cash flow | $54.6M | $78.8M | $137.8M | $49.6M | $97.0M | $49.4M |
| Free cash flow | $50.1M | $70.0M | $119.9M | $46.1M | $95.2M | $48.9M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | 22.9% | 43.0% | 1.5% | 9.1% | -13.5% | 15.3% |
| Net margin | -1.8% | 23.7% | -17.0% | 39.7% | -2.4% | 46.4% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $41.5M | $51.8M | $42.8M | $45.3M | $47.6M | $115.5M | $59.7M | $51.7M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$19.1M | $3.1M | -$9.6M | -$36.2M | $8.4M | $54.9M | $13.8M | $17.4M |
| Net income | -$51.9M | -$7.2M | -$31.1M | -$42.5M | $4.8M | $117.3M | $44.8M | -$13.3M |
| Diluted EPS | -$2.88 | -$0.39 | -$1.70 | -$2.21 | $0.24 | $5.68 | $2.42 | -$0.67 |
| Operating cash flow | $13.3M | $36.5M | $28.5M | -$25.4M | $15.8M | $13.1M | $45.9M | $48.7M |
| Free cash flow | $12.9M | $35.9M | $27.8M | -$25.7M | $15.6M | $13.1M | $45.9M | $48.5M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | -46.0% | 6.1% | -22.5% | -79.9% | 17.7% | 47.6% | 23.2% | 33.6% |
| Net margin | -125.0% | -13.8% | -72.6% | -93.6% | 10.2% | 101.6% | 75.1% | -25.8% |
Company news
Jul 14, 2026
- 6d agoAGEN Stock Jumps on Securing $340M Financing to Fund Strategic Pivotfinance.yahoo.com
- 6d agoLigand Completes Acquisition of XOMA Royalty, Creating a Portfolio of More than 200 Biopharmaceutical Royalty Assetsfinance.yahoo.com
- 6d agoXOMA Royalty Announces Closing of Its Acquisition by Ligandfinance.yahoo.com
- 6d agoAgenus (AGEN) Moves 82.7% Higher: Will This Strength Last?finance.yahoo.com
Jul 13, 2026
- 7d agoAgenus shares surge as company secures up to $340M to advance colon cancer trialproactiveinvestors.com
- 7d ago3 Overlooked Stocks Positioned for the Next Market Rotationmarketbeat.com
- 7d agoAgenus Shares Rise After Securing Up to $340 Million Financing Package (AGEN)investorshub.advfn.com
- 7d ago5 Stock Setups Where Wall Street Sees the Most Upside Right Now247wallst.com
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-07-01 | Reardon Andrew· CLO & Secretary | Sale | 1,119 | $311.72 | $348,814.68 | filing |
| 2026-07-01 | Reardon Andrew· CLO & Secretary | Sale | 1,081 | $312.28 | $337,572.95 | filing |
| 2026-07-01 | Reardon Andrew· CLO & Secretary | Sale | 900 | $315.78 | $284,199.75 | filing |
| 2026-07-01 | Reardon Andrew· CLO & Secretary | Option exercise | 5,000 | $52.27 | $261,350.00 | filing |
| 2026-07-01 | Reardon Andrew· CLO & Secretary | Sale | 700 | $313.46 | $219,420.18 | filing |
| 2026-07-01 | Reardon Andrew· CLO & Secretary | Sale | 600 | $317.15 | $190,291.02 | filing |
| 2026-07-01 | Reardon Andrew· CLO & Secretary | Sale | 396 | $308.99 | $122,359.49 | filing |
| 2026-07-01 | Reardon Andrew· CLO & Secretary | Sale | 104 | $310.20 | $32,261.04 | filing |
| 2026-07-01 | Reardon Andrew· CLO & Secretary | Sale | 100 | $314.58 | $31,457.88 | filing |
| 2026-06-30 | Reardon Andrew· CLO & Secretary | J | 132 | $160.71 | $21,213.65 | filing |
| 2026-06-30 | Davis Todd C· Chief Executive Officer | J | 132 | $160.71 | $21,213.65 | filing |
| 2026-06-30 | Espinoza Octavio· Chief Financial Officer | J | 17 | $160.71 | $2,732.06 | filing |
| 2026-06-16 | Sabba Stephen L | Sale | 2,145 | $254.00 | $544,830.00 | filing |
| 2026-06-16 | Sabba Stephen L | Option exercise | 2,145 | $66.13 | $141,848.85 | filing |
| 2026-06-12 | Haas Jason | Sale | 3,461 | $256.08 | $886,286.30 | filing |
| 2026-06-12 | Haas Jason | Sale | 3,000 | $255.01 | $765,033.90 | filing |
| 2026-06-12 | Haas Jason | Option exercise | 3,000 | $51.56 | $154,680.00 | filing |
| 2026-06-12 | Haas Jason | Option exercise | 1,000 | $51.56 | $51,560.00 | filing |
| 2026-06-11 | Aryeh Jason | Sale | 4,500 | $250.00 | $1.1M | filing |
| 2026-06-10 | LAMATTINA JOHN L | Sale | 3,405 | $251.62 | $856,751.80 | filing |
| 2026-06-10 | LAMATTINA JOHN L | Sale | 697 | $249.53 | $173,924.22 | filing |
| 2026-06-10 | Aryeh Jason | Sale | 500 | $250.00 | $125,000.00 | filing |
| 2026-06-10 | LAMATTINA JOHN L | Sale | 257 | $247.22 | $63,536.49 | filing |
| 2026-06-10 | LAMATTINA JOHN L | Sale | 232 | $248.11 | $57,561.78 | filing |
| 2026-06-05 | Zimmermann Martine | Tax withholding | 182 | $237.00 | $43,134.00 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.